Aeterna Zentaris spikes as FDA accepts NDA for filing

The FDA accepts Aeterna Zentaris' (AEZS +4.1%) NDA for macimorelin acetate in AGHD for filing.

The application was submitted in November.

Approval would make macimorelin acetate the "the first orally-administered product that induces growth hormone release to evaluate AGHD."

PDUFA date: November 5, 2014. (PR)

From other sites
Comments (1)
  • jjjorgen
    , contributor
    Comments (358) | Send Message
    Pathetic management in place for this company. Over a year late on this NDA. Drug may be worth $2 million a year in sales. Sell on the slight rise.
    6 Jan 2014, 02:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs